JPMorgan Chase & Co. Initiates Coverage on Savara (NASDAQ:SVRA)

Stock analysts at JPMorgan Chase & Co. started coverage on shares of Savara (NASDAQ:SVRA) in a research report issued on Wednesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $12.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 148.45% from the stock’s current price.

Other analysts also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Royal Bank Of Canada set a $10.00 price objective on shares of Savara in a research report on Wednesday. Finally, Citigroup reiterated a “market outperform” rating on shares of Savara in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.25.

Savara Stock Performance

SVRA opened at $4.83 on Wednesday. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The stock’s 50 day moving average price is $5.33 and its two-hundred day moving average price is $5.41. The firm has a market capitalization of $992.37 million, a P/E ratio of -8.33 and a beta of 0.20. Savara has a 12-month low of $3.35 and a 12-month high of $7.01.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, equities analysts forecast that Savara will post -0.61 earnings per share for the current year.

Institutional Trading of Savara

Several institutional investors have recently bought and sold shares of SVRA. BlackRock Inc. acquired a new stake in Savara in the 2nd quarter valued at about $76,966,000. Polar Capital Holdings Plc bought a new stake in shares of Savara during the fourth quarter valued at approximately $50,086,000. Nantahala Capital Management LLC bought a new stake in shares of Savara during the second quarter valued at approximately $42,977,150. Spruce Street Capital LP bought a new stake in shares of Savara during the second quarter valued at approximately $21,267,868. Finally, Pictet Asset Management Holding SA acquired a new stake in shares of Savara in the first quarter valued at approximately $12,424,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.